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Abstract
Background: Previous work from our laboratory demonstrated that IL-4Ra expression on a myeloid cell type was
responsible for enhancement of Th2-driven eosinophilic inflammation in a mouse model of allergic lung inflammation.
Subsequently, we have shown that IL-4 signaling through type I IL-4 receptors on monocytes/macrophages strongly
induced activation of the IRS-2 pathway and a subset of genes characteristic of alternatively activated macrophages. The
direct effect(s) of IL-4 and IL-13 on mouse eosinophils are not clear. The goal of this study was determine the effect of IL-4
and IL-13 on mouse eosinophil function.
Methods: Standard Transwell chemotaxis assay was used to assay migration of mouse eosinophils and signal transduction
was assessed by Western blotting.
Results: Here we determined that (i) mouse eosinophils express both type I and type II IL-4 receptors, (ii) in contrast to
human eosinophils, mouse eosinophils do not chemotax to IL-4 or IL-13 although (iii) pre-treatment with IL-4 but not IL-13
enhanced migration to eotaxin-1. This IL-4-mediated enhancement was dependent on type I IL-4 receptor expression: cC-
deficient eosinophils did not show enhancement of migratory capacity when pre-treated with IL-4. In addition, mouse
eosinophils responded to IL-4 with the robust tyrosine phosphorylation of STAT6 and IRS-2, while IL-13-induced responses
were considerably weaker.
Conclusions: The presence of IL-4 in combination with eotaxin-1 in the allergic inflammatory milieu could potentiate
infiltration of eosinophils into the lungs. Therapies that block IL-4 and chemokine receptors on eosinophils might be more
effective clinically in reducing eosinophilic lung inflammation.
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Introduction
Eosinophils play a critical role in the pathogenesis of allergic
asthma, both in human asthmatics and in mouse models of the
disease [1–3]. They are also an important host defense mechanism
against helminth parasite infection [4,5]. Eosinophilic infiltration
of the lung parenchyma and airways in response to chemotactic
gradients is a characteristic feature of allergic inflammation of the
lung [6]. Activated eosinophils release granules containing a wide
variety of mediators that can cause tissue damage and in-
flammation. The T-helper (Th)2 cytokines, interleukin (IL)-4 and
IL-13, are also made by these cells [7].
Interleukin-4 and IL-13 are key mediators in the development
and persistence of an allergic immune response and much
attention has been given to their relative roles during the process
[8]. IL-4 and IL-13 exert their function by binding to IL-4
receptors on the cell surface. IL-4 binds to the interleukin-4
receptor alpha (IL-4Ra) chain, which pairs with either the
common gamma chain (cC) to form type I IL-4 receptors or with
the IL-13Ra1 subunit to create type II receptors. The type II
receptor is also the IL-13 receptor but the ligand-binding subunit
is IL-13Ra1 in this case. Human eosinophils have been shown to
express IL-4Ra, both on the cell surface [9] and in pre-formed
stores on the outer membrane of their granules [10]. Engage-
ment of both types of receptor initiates activation of the signal
transducer and activator of transcription (STAT)6 pathway [11]
but only type I IL-4 receptors are capable of strongly activating
the insulin receptor substrate (IRS)-2 pathway in myeloid cells
[12]. The IRS-2 adaptor protein has the potential to trigger
a variety of signaling pathways depending on the particular
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(PI3K)/Akt, Grb/son-of-sevenless (Sos)/Rat sarcoma protein
(Ras), mammalian target of rapamycin (mTOR) and protein
kinase C (PKC) pathways.
The contribution of the type I and type II receptors to Th2
responses after allergen provocation and worm infection has been
investigated in vivo using mice deficient in the IL-13Ra1 chain
[13,14]. Cellular infiltration of the lung and airspaces in response
to challenge with either S. mansoni egg antigen [13], ovalbumin
(OVA) or IL-4 [14] was essentially unaffected by the IL-13Ra1
deficiency in these mice, suggesting that signaling through type I
IL-4R is essential in mediating eosinophilic inflammation. Since
CC chemokine production was almost completely diminished in
the IL-13Ra1-deficient mice, it was hypothesized that a type I IL-
4R-induced, CC chemokine-independent pathway that can recruit
eosinophils must play an important role.
IL-4 has been demonstrated to induce chemotaxis directly on
eosinophils purified from human atopic donors and enhance
their chemotaxis to CCL5 (RANTES, Regulated on Activation
Normal T-cell Expressed and Secreted [9]). Previous work from
our laboratory demonstrated that IL-4Ra expression on a mye-
loid cell type enhanced Th2-driven eosinophilic inflammation in
an OVA sensitization and challenge mouse model of allergic lung
inflammation [15]. Given the importance of the eosinophil in
allergic inflammation, we investigated whether mouse eosinophils
responded directly to IL-4 and IL-13 in vitro and how these
cytokines affected the chemotactic function of the cells. We found
that mouse eosinophils express both type I and type II receptors
on their surface and mRNA for both type I and II receptor
subunits. IL-4, but not IL-13, promoted strong tyrosine
phosphorylation of STAT6 and both cytokines induced tyrosine
phosphorylation of IRS-2. Phosphorylation of other signaling
intermediates [AKT, p38, extracellular-regulated kinase (ERK)1/
2] after IL-4/IL-13 stimulation was not detected in these cells.
IL-4 was able to enhance eosinophil migration to CC
chemokines better than IL-13. Pre-treatment of mouse eosino-
phils with IL-4 but not IL-13 enhanced migration to eotaxin-1.
This enhancement of migration was dependent on expression of
the type I IL-4 receptor, as eosinophils deficient in the cC
subunit did not show this IL-4-enhanced migratory capacity.
These data suggest that mouse eosinophils are more responsive
to IL-4 than IL-13 and the presence of this cytokine in
combination with CC chemokines, as is found in an allergic
setting in vivo, would potentiate the infiltration of eosinophils into
lung tissue.
Materials and Methods
Mice and Reagents
All experiments were conducted under the approval of the
University of Maryland Baltimore Institutional Animal Care and
Use Committee. IL-5 transgenic (Tg) mice on a C57BL/6
background [16] were provided by Dr James Lee at the Mayo
Clinic, Scottsdale, AZ and were maintained as described [17]. IL-
5 transgene-positive mice were identified by PCR of ear punch
samples as described [16]. Mice deficient for cC (B6.129S4-
Il2rg
tm1Wjl/J) and wildtype (WT) C57BL/6 were purchased from
the Jackson Laboratories, Bar Harbor, ME. The mouse macro-
phage cell line, RAW 264.7, was purchased from the ATCC
(Manassas, VA). IL-4 and IL-13 were purchased from R & D
Systems (Minneapolis, MN) and all chemokines, IL-5, stem cell
factor (SCF) and Flt3-ligand (Flt3-L) were purchased from
Peprotech (Rocky Hill, NJ).
Isolation of Mouse Eosinophils
Mouse eosinophils constitute about 60% of the leukocytes in the
peripheral blood of IL-5 Tg mice [16] and they were purified from
peripheral blood of IL-5 Tg mice following cardiac puncture as
described [17,18]. Briefly, the buffy coat layer from Percoll E-
separated blood [18] was subjected to red cell lysis with 0.2%
NaCl to minimize granule alterations [19] and negative selection
with magnetic anti-CD90 (Thy 1.2) and anti-CD45R (B220)
microbeads (Miltenyi Biotec, Auburn, CA) as per the manufac-
turer’s instruction. The purity of the eosinophils was determined
by double-staining with anti-CC chemokine receptor (CCR)3,
either in combination with anti-Gr-1 (both from BD Biosciences)
or anti-Siglec F antibodies (BD Biosciences) by fluorescence-
activated cell sorting (FACS) and also by DiffQuik staining (Dade
Boehringer AG) following cytospin (Figure 1A). Preparations were
routinely .90% CCR3/Gr-1 double-positive, and .90% Siglec
F-positive and the mouse eosinophils had a typical ring-shaped
nuclear morphology and red granules by microscopic evaluation
(Figure 1A). The viability of the cells after purification was .97%
by propidium iodide exclusion.
Eosinophils were also generated by differentiation of bone
marrow harvested from cC
+/+ or cC
2/2 mice using stem cell
factor (SCF), Flt3-ligand (Flt3-L) and IL-5 as described [20].
Briefly, bone marrow was harvested, red cells were lysed and the
cells were cultured in SCF and Flt-3L for four days, followed by
culture in IL-5 for an additional ten days. Similar numbers of
eosinophils were generated from both strains after the fourteenth
day of culture. Cell viability was .78% by Trypan blue exclusion
and the eosinophils from both strains were .76% Siglec F/Gr-1
double-positive by FACS analysis. After day 14, the cells were
harvested and washed in RPMI containing 5% bovine serum
albumin (Sigma). Chemotactic responses were evaluated as
described below. Eosinophils derived from cC
+/+ or cC
2/2 mice
migrated similarly in response to eotaxin-1, indicating no defect in
chemokine-elicited migration.
Allergic lung sensitization. Mice were sensitized and
challenged with chicken egg ovalbumin using a modified protocol
described by Wang et al [21]. Each mouse was immunized with
either 100 mg of OVA/alum or alum alone on day 1 and again on
day 6. After the last sensitization step, mice were challenged with
aerosolized 1% OVA in phosphate-buffered saline (PBS) for 40
minutes each day on days 12 and 14 and BALF was collected 48
hours after the last OVA challenge. The BALF was collected by
lavaging the lungs with 1 ml PBS and cell-free supernatant was
isolated and stored at –70uC until use. BALF from three mice in
each treatment group was pooled and diluted 1:4 in RPMI/5%
BSA before being added to the bottom chamber of the Transwell
plate.
Transmigration Assay
Chemotaxis of purified eosinophils was performed as described
[17] with modifications [18]. A typical Transwell assay (Costar,
6.5 mm diameter, 5 mm pore size) was used. The eosinophils
prepared as described above were washed and resuspended in
RPMI containing 5% bovine serum albumin (Sigma). Five610
5
cells in 200 mL were added to the top chamber and 500 mLo f
recombinant mouse chemokine, bronchoalveolar lavage fluid
(BALF) harvested from OVA-primed mice (described above), IL-
4, or IL-13 were added to the bottom chamber. The eosinophils
were allowed to migrate for two hours at 37uC in the tissue culture
incubator. For experiments involving pre-treatment of eosinophils
with cytokines, purified cells were incubated for 30 minutes at
37uC with increasing concentrations of IL-4 or IL-13. Pre-treated
cells were then either added directly to the Transwell chamber or
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was evaluated by FACS using CountBright
TM Absolute counting
beads (Invitrogen/Molecular Probes) as per the manufacturer’s
instructions. Migration is expressed as the fold change in
migration. Fold change was calculated as the number of cells that
migrated in response to a stimulating agent divided by the number
that migrated in response to medium alone. The viability of
migrated cells after the chemotaxis assay by propidium iodide
exclusion was $91%.
Signaling Analysis
Purified eosinophils were serum-starved in RPMI 1640 at
a density of 10610
6 cells/mL for two hours prior to signaling
analysis. Cells were then stimulated with eotaxin 1, IL-4, or IL-13
for 15 min at 37uC. Cells were then washed in ice-cold PBS
containing 1 mM sodium orthovanadate, pelleted and lysed in
lysis buffer [12] with additional 100 nM calyculin A and 5 mM
caproic acid. Lysates were analyzed by Western blot for
phosphorylated STAT6
Tyr641, AKT
Ser473, p38
Thr180/Tyr182 and
ERK1/2
Thr202/Tyr204 and a-tubulin as described [12]. Tyrosine
phosphorylation of IRS-2 was analyzed by immunoprecipitation
with antibodies to IRS-2 followed by Western blot with anti-
phosphotyrosine antibodies.
Receptor Analysis
Purified eosinophils were stained with specific antibodies to
mouse IL-4Ra (BD Biosciences), cC (BD Biosciences) or IL-13Ra1
and were analyzed by FACS as described previously [12]. The anti-
mouse IL-13Ra1 monoclonal antibody was developed in the
laboratory of Ray Donnelly against a peptide in the D1 domain of
the mouse IL-13Ra1 protein [22]. This antibody binds specifically
to the IL-13Ra1 chain and does not cross-react with IL-4Ra, cCo r
IL-13Ra2. After washing away unbound anti-mouse IL-13Ra1
antibody, cells were incubated with an anti-mouse-phycoerythrin
antibodyandfluorescencewasanalyzedbyFACS.Expressionofthe
mRNA for each of the type I and type II receptor components was
determined by quantitative RealTime PCR as follows. Total RNA
was isolated from purified eosinophils or from the macrophage cell
line RAW264.7 as a positive control using the RNeasy kit (Qiagen)
and converted to cDNA with the SuperScript III RTase kit
(Invitrogen), both according to the manufacturer’s instructions.
RealTime PCR was performed with the following primer sets:
hypoxanthine phosphoribosyltransferase (Hprt) forward, 59-
GCTGACCTGCTGGATTACATTAA-39 and Hprt reverse59-
TGATCATTACAGTAGCTCTTCAGTCTGA-39, Il-4ra for-
ward, 59-ATCTGCGTGCTTGCTGGTTCT-39 and Il-4ra re-
verse, 59-CTGGTATCTGTCTGATTGGACCG-39, cC forward,
59-GTGCAGTACCGGAGCAAC AGA-39 AND cC reverse, 59-
Figure 1. Purification and characterization of mouse eosino-
phils from IL-5 Tg mice. (A). FACS and cytospin analysis of peripheral
blood ‘‘buffy coat’’ cells prior to and after MACS column purification.
Peripheral blood from IL-5 Tg mice was spun over Percoll, the red cells
were lysed and the eosinophils were purified using a negative
separation MACS column-based strategy as described [17] with
modifications [18]. The purity of the eosinophil preparation was
assessed by FACS double-staining for the surface markers, Gr-1 and
CCR3, as well as Siglec F and by examination of cytospins following
DiffQuik staining (406). Red-stained eosinophilic granules are clearly
visible in the cells at 1006magnification. (B). Eosinophils were purified
as described in the Methods. Eosinophils (5 610
5 per Transwell insert)
were placed into the upper chamber of a 24-well Transwell chemotaxis
assay plate in duplicate with increasing concentrations of eotaxin-1 in
the lower chamber and incubated at 37uC for 2 hours [18]. The total
number of live cells that had migrated into the bottom chamber at each
concentration was counted and divided by the number that migrated
to medium alone to give the fold change above control, which was
plotted against eotaxin-1 concentration. (C). Migration of mouse
eosinophils to CCR1, CCR3, CCR4 agonists and BALF from Alum- and
OVA/Alum-sensitized and challenged mice. Thirty nanomolar solutions
of each chemokine or BALF from mice subjected to ovalbumin
sensitization and challenge or alum control diluted 1:4 [15] were used
in the chemotaxis assay as described in (B) in triplicate. Migrated cells
were collected after 2 hours and counted by FACS with CountBright
TM
beads as described in the Methods. (*P,0.05, compared to medium
control or Alum-treated control).
doi:10.1371/journal.pone.0039673.g001
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CATCTTCTCCTCAAAAATGGTGCC-39, Il-13ra1 reverse, 59-
GGATTATG ACTGCCACTGCGAC-39, IL-13ra2 forward, 59-
CACACCTGGAGGACCCATTC-39 and Il-13ra2 reverse, 59-
GTGGCAGACTCCCAGGAAATAT-39. The quantitation of the
mRNA by RealTime PCR from duplicate wells is expressed using
relative quantitation, expressed in the standard format of 2
–DDCt.
The relative expression of receptor subunit mRNA from mouse
eosinophils was compared to the amount of expression in the RAW
cell line, the positive control (2
–DDCt =1). The PCR products were
also resolved on a 3% agarose gel and visualized by ethidium
bromide staining.
Statistical Analyses
Data were analyzed by Student t-test or one-way ANOVA with
Fisher’s least significant difference post-hoc test as appropriate.
Differences between groups were considered significant when
P,0.05.
Results
IL-4 Receptor Expression on Mouse Eosinophils
Eosinophils isolated from IL-5 transgenic mice were greater
than 91% pure based on FACS analysis with CCR3/Gr-1/Siglec
F and appeared morphologically normal by microscopic exami-
nation following cytospin and DiffQuik staining (Figure 1A). The
mouse eosinophils were TER119, CD16 and CCR5-negative and
had high side scatter by FACS. To characterize the responsiveness
of these purified eosinophils, a concentration-response analysis of
eosinophil migration to eotaxin-1 was performed (Figure 1B). The
maximum migration was observed at 30 nM eotaxin-1 (252 ng/
mL), with less migration at higher eotaxin-1 concentrations due to
desensitization typical of G-protein-coupled chemokine receptors
at high ligand concentrations. Therefore, 30 nM eotaxin-1 was
used in subsequent chemotaxis experiments. We also verified the
ability of our purified cells to migrate to a variety of different
recombinant mouse chemokines. To compare the migration of our
purified eosinophils to 30 nM eotaxin-1 to other mouse CC and
CXC chemokines, equimolar concentrations (30 nM) of various
mouse CC and CXC chemokines were placed in the bottom
chamber and migration of eosinophils was measured after two
hours (Figure 1C). Mouse eosinophils migrated best to the CCR3
ligands, eotaxin-2 and -1 as has been previously described [17].
Migration of the cells to BALF from OVA-challenged mice was
also significantly elevated above the migration to BALF from
control mice treated with alum. Migration to the other ligands
(KC, macrophage inflammatory protein (MIP)1b and human
eotaxin-3) was not significantly different than migration to
medium alone, as was observed previously [17].
RealTime PCR and FACS analysis was used to determine the
expression of mRNA and surface protein for the different
components of the IL-4 and IL-13 receptor complexes. Mouse
eosinophils express mRNA for the common c chain (cC), IL-4Ra,
IL-13Ra1 and IL-13Ra2 as determined by RealTime PCR
(Figure 2A). Mouse eosinophils also express, cC, IL-4Ra and IL-
13Ra1 protein on the cell surface as detected by FACS (Figure 2B),
similar to the surface expression pattern seen on human
eosinophils by Myrtek et al [23]. The expression of cC and IL-
4Ra chain on primary mouse bone marrow-derived macrophages
(BMM) isolated from cC
+/+ or cC
2/2 and on the mouse
macrophage cell line, RAW 264.7, is shown for comparison to
the purified mouse eosinophils. Expression of these receptor
components on primary eosinophils was similar to expression on
primary BMM. These results are consistent with equilibrium
binding studies on primary cells showing that the numbers of IL-4
and IL-13 binding sites range from 50–5000 per cell [24]. These
results indicate that eosinophils express all the receptor subunits to
form both type I and type II receptors.
IL-4 Pre-treatment Enhanced Chemotaxis of Mouse
Eosinophils to Eotaxin-1
Two earlier studies noted that the cytokines IL-4 and IL-13
could induce chemotaxis in human eosinophils but with conflicting
results. Dubois et al described migration to IL-4 (10
28 to 10
210 M)
of human eosinophils derived from individuals with atopic
dermatitis and allergic asthma but not normal controls [25]. In
contrast, concentrations of $60 ng/mL IL-13 but not IL-4 were
found to be chemotactic for human eosinophils purified from
normal volunteers [26]. Intraperitoneal or intradermal injection of
mice with IL-4 induced eosinophilic infiltration [27]. Whether
mouse eosinophils respond directly to IL-4 or IL-13 in vitro was not
known. Therefore, we used primary mouse eosinophils in an
in vitro Transwell chemotaxis assay to test migration to ng/mL
concentrations of recombinant mouse IL-4, IL-13 or 30 nM
eotaxin-1 alone or in the presence or absence of IL-4 or IL-13.
We found that neither IL-4 nor IL-13 induced migration of
eosinophils or enhanced migration of mouse eosinophils to 30 nM
eotaxin-1 when they were placed in the bottom chamber in
increasing concentration (Figure 3A, representative data from one
experiment and 3B, mean data from multiple experiments). There
was a trend to enhancement of migration compared to eotaxin-1
alone at the higher concentrations of cytokine although statistical
significance was not reached. Because we were concerned that the
eosinophils were at maximum migratory capacity at 30 nM
eotaxin-1 and we may be missing any enhancing effects of the
addition of the cytokines, we repeated the chemotaxis experiments
using a lower dose of eotaxin-1. When a suboptimal concentration
(10 nM) eotaxin-1 was used in the bottom chamber with either IL-
4 or IL-13, the modest enhancement of eosinophil migration
compared to 10 nM eotaxin-1 alone was not greater than that
observed at 30 nM eotaxin-1 in the presence or absence of
cytokine (data not shown). However, we found that pre-treatment
of the mouse eosinophils for 30 minutes with IL-4, but not with IL-
13, augmented the chemotactic response of the mouse eosinophils
to eotaxin-1 (Figure 4). A representative experiment directly
comparing the effect of increasing concentrations of IL-4 and IL-
13 pre-treatment on migration to eotaxin-1 is shown (Figure 4A).
In multiple independent experiments, pre-treatment with IL-4
Figure 2. Expression of mRNA and surface protein for components of the IL-4/IL-13 receptor complex on mouse eosinophils. (A).
Expression of mRNA for the different subunits of the IL-4/IL-13 receptor complex. RNA was extracted from purified eosinophils and the mouse
macrophage cell line, RAW 264.7, and cDNA was synthesized. Relative quantitation by RealTime PCR with specific primer pairs for each receptor
subunit was performed, using the standard 2
2DDCt method, and the products were resolved on a 3% agarose gel. The amount of expressed mRNA for
each subunit from mouse eosinophils (filled bars) relative to the amount in the control RAW cell line (=1, open bars) was graphed. (B). Cell surface
expression of the IL-4/IL-13 receptor subunits on mouse eosinophils. FACS analysis using specific antibodies to each receptor subunit was performed.
Representative FACS histograms from one experiment (of four to five independent experiments) are shown with staining with specific antibody (solid
black line) and isotype-matched control antibody (dotted line). Receptor staining on mouse bone marrow-derived macrophages from wildtype and
cC-deficient mice, generated as described [12], and to RAW 264.7 cells is shown for comparison.
doi:10.1371/journal.pone.0039673.g002
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to IL-4 (left panel) and IL-13 (right panel) in the presence (filled bars) or absence (open bars) of 30 nM eotaxin-1 was measured. The indicated
concentrations of IL-4 were placed in the lower chamber and 5 x 10
5 eosinophils were placed in the upper chamber. A representative experiment is
shown. (B). Average data from multiple independent chemotaxis experiments performed as in (A) using IL-4 or IL-13 with (squares) or without (circles)
eotaxin in the lower chamber (n=2–4). For the IL-4 graph, number of migrated cells to medium=9,7336 SEM 2,468 and to eotaxin-1=54,4446 SEM
10,926 and for the IL-13 graph, number of migrated cells to medium=4,4786 SEM 689 and to eotaxin-1=56,6546 SEM 4,949.
doi:10.1371/journal.pone.0039673.g003
Figure 4. Pre-treatment with IL-4 but not IL-13 enhanced migration of purified mouse eosinophils to eotaxin-1 and eotaxin-2.
Eosinophils were purified as described in the Methods. (A). Eosinophils were then incubated with various concentrations of IL-4 or IL-13 at 37uC for 30
minutes. The treated cells were washed and then placed (5610
5) into the upper chamber insert of the Transwell plate; the lower chamber contained
either 0 or 30 nM eotaxin-1. The chemotaxis assay was performed and the number of migrated cells was counted as described in Figure 1. A
representative experiment is shown. (B) Average data from three independent chemotaxis experiments (n=3;*P,0.05, compared to migration to
eotaxin-1 alone). For the IL-4 graph, number of migrated cells to medium=11,6146 SEM 3,257 and to eotaxin-1=102,4356 SEM 27,964 and for the
IL-13 graph, number of migrated cells to medium=8,5816 SEM 2,163 and to eotaxin-1=75,6516 SEM 20,436. (C, left panel) Time of IL-4 pre-
treatment of eosinophils prior to chemotaxis. Eosinophils were pre-treated with 10 ng/mL IL-4 for the indicated times, subjected to chemotaxis to
30 nM eotaxin-1 and counting as in (A). P,0.05. (C, right panel) Eosinophils were pre-treated with 10 ng/mL IL-4 for the indicated time, subjected to
chemotaxis to 30 nM eotaxin-2 and counting as in (A). P,0.05.
doi:10.1371/journal.pone.0039673.g004
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while pre-treatment with IL-13 (right panel, squares) did not
(Figure 4B). Migration was not enhanced at a suboptimal
concentration of eotaxin-1 (10 nM) in the bottom chamber
following cytokine pre-treatment compared to 10 nM eotaxin-1
alone (data not shown). The effect of the time of IL-4 pre-
treatment (10 ng/mL) on migration of eosinophils to 30 nM
eotaxin-1 was also tested (Figure 4C, left panel). A 30 minute pre-
treatment of the cells with IL-4 enhanced migration to eotaxin-1
optimally. Migration of eosinophils to 30 nM eotaxin-2 was also
enhanced to a similar degree (approximately three-fold) by pre-
treatment with IL-4 (Figure 4C, right panel).
IL-4 and IL-13-induced Signaling in Mouse Eosinophils
Previous data from our lab demonstrated that IL-4 and IL-13
can exert differential activation of signaling molecules downstream
of the IL-4 receptor complex, in particular on the IRS-2 pathway,
despite the fact that type I and type II receptors share a common
subunit, the IL-4Ra chain. Because pre-treatment with IL-4
enhanced chemotaxis while IL-13 did not, we reasoned that the
two cytokines may have differential effects on signaling pathways.
To this end, a variety of signaling pathways were analyzed by
Western blotting of eosinophil lysates after stimulation with IL-4
and IL-13 (Figure 5). The IL-4-induced tyrosine phosphorylation
of STAT6 in the mouse eosinophils was approximately ten-fold
above unstimulated (P,0.05) but IL-13 induced phospho-STAT6
only two-fold above the unstimulated signal at the equivalent
cytokine concentration (Figure 5B). This contrasts with our
observations in mouse BMM where stimulation with high
concentrations of IL-4 and IL-13 induced equivalent amounts of
phospho-STAT6 [12]. Both cytokines stimulated tyrosine phos-
phorylation of IRS-2, with IL-4 again inducing a more robust
response than IL-13. The IL-4-induced phosphorylation of IRS-2
was six-fold of the unstimulated amount while the IL-13-induced
signal was two-fold over background, consistent with our previous
observations in mouse BMM [12]. Neither cytokine elicited
significant phosphorylation of ERK1/2, p38 or AKT relative to
unstimulated eosinophils. This finding contrasts with observations
that IL-4 elicited p38 phosphorylation in human eosinophils [28].
To determine whether the increased migration to eotaxin-1
following IL-4 stimulation might be due to increased surface
expression of the eotaxin-1 receptor, CCR3, on the eosinophils,
we analyzed the CCR3 expression on the cell surface by FACS in
IL-4- and IL-13-pre-treated cells compared to unstimulated cells
(Figure 6A). There was little change in the cell surface expression
of CCR3 following stimulation with IL-4 or IL-13 (at 1, 10 or
100 ng/mL IL-4 or IL-13), possibly because CCR3 expression on
eosinophils derived from IL-5 Tg mice is already elevated
approximately three-fold above that measured on wildtype
eosinophils [29].
Although there was no change in the amount of CCR3
expressed on the cell surface following incubation with IL-4, we
tested whether IL-4 augmented eosinophil signaling responses to
eotaxin-1 downstream of the chemokine receptor (Figure 6B).
Eotaxin-1 induced the phosphorylation of ERK1/2, as anticipated
from studies of human eosinophils [30–32]. However, IL-4 did not
augment eotaxin-1-induced ERK phosphorylation in the mouse
cells and neither did IL-13. Eotaxin-1 stimulation of mouse
eosinophils induced a small amount of phosphorylation of p38 and
AKT on Ser473, as has been described for stimulation of human
eosinophils with eotaxin [32] and other chemoattractants [30].
Neither treatment with IL-4 nor IL-13 in combination with
eotaxin-1 resulted in a greater amount of the phosphorylated
Figure 5. Signaling responses to IL-4 and IL-13 in mouse eosinophils. (A) Eosinophils were purified as described in the Methods. The cells
were serum-starved for 2 hours prior to stimulation with 20 ng/mL IL-4 (‘‘4’’) or IL-13 (‘‘13’’) for 15 mins or no stimulation (‘‘–’’). Eosinophil cell lysates
were prepared as described in the Methods and subjected to SDS-PAGE and Western blotting with antibodies specific for the phosphorylated form of
the particular signaling protein. Blots were stripped and re-probed with antibodies specific for the unphosphorylated form of the protein. Films from
one representative experiment are shown. (B). Densitometric analysis of Western blot films. Films from independent experiments were scanned and
the amount of phosphoprotein/total target protein was quantitated by densitometry. This ratio was normalized for loading (to a-tubulin) and
graphed with the amount of phosphoprotein in unstimulated cells equal to 1). Average data from three to four independent experiments are shown
(*P,0.05).
doi:10.1371/journal.pone.0039673.g005
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eotaxin-1 alone.
The Role of type I IL-4 Receptor in Cytokine-induced
Enhancement of Chemotaxis
Since IL-4 enhanced chemotaxis to eotaxin-1 while IL-13 did
not, we hypothesized that the enhancement was activated
specifically by the type I receptor, the receptor complex unique
for IL-4. To test this hypothesis, chemotaxis studies were
performed using eosinophils lacking expression of cC, which is
required to form functional type I IL-4 receptor complexes.
Eosinophils were prepared in vitro by culturing bone marrow
isolated from cC
+/+ or cC
2/2 mice with stem cell factor, Flt3-L
and IL-5 (bmEos, [20]. Equal numbers of viable eosinophils that
were 74% CCR3/Gr-1-double positive and 78% and 76%
positive for Siglec-F were obtained from cC
+/+ and cC
2/2 bone
marrow respectively. Expression of cC, IL-4Ra and IL-13Ra1
on both cC
+/+ or cC
2/2 bone marrow-derived eosinophils
showed a similar pattern to that seen on eosinophils purified
from the IL-5 Tg mice (data not shown), with the exception of
the cC subunit that was absent on the bmEos derived from the
cC-deficient animals, as expected. Surface expression of IL-
13Ra2 could not be evaluated due to lack of available reagents
for mouse cells and quantitative PCR is not a reliable measure of
protein expression at the cell surface.
We found that eotaxin-1 induced migration of cC
+/+ and
cC
2/2 bmEos by four to six-fold (Figure 7). This level of
chemotaxis was lower than that observed using eosinophils
prepared from the peripheral blood of IL-5 Tg mice (which was
typically eight to ten-fold above medium control, Figure 1). This
observation is consistent with previous studies of bmEo migration
to eotaxin-1, (2.25-fold above medium control in response to
100 ng/mL eotaxin-1, [20]). We chose to pre-treat the bmEos
with 10 ng/mL IL-4 as this pre-treatment concentration elicited
Figure 6. Effect of pre-treatment with IL-4 and IL-13 on CCR3 expression and eotaxin-1 signaling in mouse eosinophils. (A).
Eosinophils were treated with (heavy solid line) or without (light solid line) 100 ng/mL IL-4 (left panel) or IL-13 (right panel) for 30 min and FACS
analysis with specific antibodies to CCR3 (solid lines), an isotype control (dotted) or unstained (dashed line) was performed as described (Figure 1). (B)
The cells were serum-starved for 2 hours prior to stimulation with 20 ng/mL IL-4 (‘‘4’’) or IL-13 (‘‘13’’) for 15 mins or 30 nM eotaxin-1 (‘‘eot’’) for 1
minute or no stimulation (‘‘–’’) as indicated. Cell lysates were prepared and analyzed by Western blotting as Figure 5.
doi:10.1371/journal.pone.0039673.g006
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Pre-treatment of the cC
+/+ bmEos with IL-4 enhanced migration
to eotaxin-1, compared to migration of the untreated cells to
eotaxin-1 alone (P =0.051). In contrast, IL-4 pre-treatment
clearly did not enhance chemotaxis of cC
2/2 bmEos in response
to eotaxin-1. These data indicate that the type I IL-4 receptor is
required for the IL-4-induced enhancement of eosinophil
migration induced by eoxtaxin-1.
Discussion
Eosinophilic infiltration of the airways is characteristic of an
allergic inflammatory response in the lung and migration of these
cells from the blood to the airways occurs as a result of chemokine
gradients secreted by lung resident cells, such as the airway
epithelium. In vitro experiments using purified human eosinophils
have demonstrated chemotactic movement to both Th2-type
cytokines, IL-4 [25,33] and IL-13 [26]. Overnight incubation with
IL-4 enhanced the migration of human eosinophils to RANTES
[9]. Human eosinophils express the cC chain of the type I IL-4
receptor on their surface and expression of IL-4Ra is constitutive
[9]. A previous report from our laboratory demonstrated that non-
lymphoid, bone marrow-derived cell(s) that expresses the IL-4Ra
chain contributed to the severity of lung inflammation and mucus
production in a mouse model of an ovalbumin-induced allergic
lung inflammation [15]. Careful characterization of the expression
pattern of IL-4/IL-13 receptors on mouse eosinophils and how the
signaling and chemotactic responses of mouse eosinophils are
affected by these Th2 cytokines is unknown. In our study, we
found that mouse eosinophils express the cC, IL-4Ra, and IL-
13Ra1 receptor chains on their surface, and that pre-treatment
with IL-4 but not IL-13 enhanced cell migration to eotaxin-1. The
enhancement of chemotaxis following pre-treatment with IL-4 was
not due to induction of CCR3 on the surface of the eosinophils,
confirming earlier studies of modulation of CCR3 expression on
human eosinophils by various cytokines [34]. We found that the
enhancement of chemotaxis following pre-treatment with IL-4 was
mediated by the type I IL-4 receptor because bone marrow-
derived eosinophils from cC-deficient mice showed no enhanced
migration to eotaxin-1 following IL-4 pre-treatment compared to
the wildtype cells. We also show for the first time that mouse
eosinophils responded to IL-4 by inducing strong tyrosine
phosphorylation of STAT6 and IRS-2. In contrast, IL-13 only
induced weak tyrosine phosphorylation of these downstream
signaling proteins. ERK and p38 were not phosphorylated in
response to IL-4/213 but there was a slight induction of phospho-
AKT
Ser473 following IL-4 stimulation but less with IL-13.
These findings are important in the context of eosinophilic
chemotactic responses in allergic disease. They suggest that
eosinophils can become more migratory in the presence of the
Th2 cytokine IL-4. This cytokine can also inhibit eosinophil
apoptosis [35], stimulate chemokine (MIP-1a and RANTES)
synthesis and release of MBP. Therefore, IL-4 priming could
augment the infiltration of eosinophils into the lung tissue. Once
the eosinophils have migrated into the lung tissue, IL-4 from
airway mucosal mast cells and CD4+ T-cells could continue to
prime them for migration to the airways. Although the concentra-
tions of cytokines utilized in our study are typical of in vitro studies
with this cell type, they are above those measured in physiological
fluids (BALF, serum) in the setting of allergic inflammation in
humans and mice. However, BALF is much diluted upon
collection and IL-4 and IL-5 are often unmeasurable in serum,
these higher concentrations may be representative of those found
at the ‘‘allergic synapse’’ – the close interface between migrating
eosinophils and degranulating mast cells, basophils or Th2 cells
which produce high levels of the cytokine [36]. IL-4 is believed to
be involved in the early phases of the allergic inflammatory
response, with IL-13 acting later as an ‘‘effector’’ cytokine. This
temporal difference could explain how our data presented here fit
with the observation from earlier in vivo studies, showing IL-4
secretion into the BALF peaked at 24 hours post-intranasal
challenge, followed by an influx of eosinophils into the BALF and
lung tissue that peaked at 48 hours [37]. From our experiments
comparing the effect of IL-4 and IL-13 on migration and the
movement of IL-4-treated WT and cC-deficient eosinophils, we
conclude that IL-4, but not IL-13, acting through the type I IL-4
receptor plays a significant role in eosinophil migration. This
conclusion is supported by the observation that there was only
a minor reduction in eosinophilic inflammation in response to
OVA and to IL-4 in the IL-13Ra1-deficient (type II receptor-
deficient) mice despite the absence of eosinophilic chemokines
[14]. Taken together with our data, these observations point to
a direct role for type I IL-4 receptor signaling in eosinophil
migration. In light of recent reviews on the subject, our study
strengthens the notion of Th2-cytokine cross-talk in both
directions between eosinophils and Th2-cells in allergic inflam-
mation [38–40].
We observed a difference in the magnitude of tyrosine
phosphorylation of STAT6 and IRS-2 following stimulation
with IL-4 compared to IL-13. IL-4 elicited robust tyrosine
phosphorylation of STAT6 and IRS-2 compared to IL-13
cytokine in these experiments. This difference in intensity of
tyrosine phosphorylation is similar to that which we observed in
the airway epithelial cell line, A549 [41], in macrophages [12]
Figure 7. Migration of bone marrow-derived eosinophils
(bmEos) from cC
+/+ and cC
2/2 mice to eotaxin-1. Eosinophils were
differentiatedfromthebonemarrowofcC
+/+(blackbars)orcC
2/2(open
bars) mice in vitro as described in the Methods. The cells were either
untreated or primed with 10 ng/mL IL-4 for 30 min prior to placement
into the upper chamber of the Transwell chemotaxis assay. Eotaxin-1
(30 nM) was placed in the lower chamber. Migrated eosinophils from
triplicate wells were counted as described in Figure 1. The average data
from two experiments performed in triplicate are shown (* P,0.05,
comparedto mediumcontrol).For cC
+/+,meannumberof cellsmigrated
to medium=44,5676 SEM 10,947; to eotaxin-1=155,8176 SEM 34,864
andIL-4pre-treatedcellstoeotaxin-1=217,0436SEM24,531.ForcC
2/2,
mean number of cells migrated to medium =51,6406 SEM 12,840; to
eotaxin-1=149,8626 SEM 13,133 and IL-4 pre-treated cells to eotaxin-
1=145,7686 SEM 19,289.
doi:10.1371/journal.pone.0039673.g007
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tyrosine phosphorylation of STAT6 (and IRS-2 in macrophages)
than IL-13. However, in contrast to macrophages, the difference
in STAT6 phosphorylation induced by IL-4 versus IL-13 was
greater in eosinophils than the difference between IRS-2 tyrosine
phosphorylation elicited by these two cytokines. The mouse
eosinophils expressed a moderately high amount of IL-13Ra1o n
their surface, relative to cC, which can result in IL-13 being
a stronger inducer of STAT6 activation compared to IL-4, as
was observed in peritoneal versus bone marrow-derived macro-
phages [43]. It is possible that a higher threshold of IL-13Ra1
expression is necessary for the IL-13-induced phospho-STAT6
response to be more robust than the IL-4-induced response, as
was observed in the THP-1 cell line [12]. However, even at very
high concentrations (100 ng/ml), IL-13 still did not enhance
migration to eotaxin-1. Furthermore, in the absence of the type I
receptor (cC
2/2 bmEos), IL-4 pre-treatment did not enhance
chemotaxis to eotaxin-1, suggesting that the type II receptor
expressed on eosinophils is not able to mediate this response. It is
possible that the engagement of type II receptor in eosinophils
favors the activation of phosphatases dampening any activating
signal. Alternatively, expression of IL-13Ra2, the so-called
‘‘decoy’’ receptor, on mouse eosinophils may be either constitu-
tively high or cytokine-induced to inhibit IL-13 signaling [44].
We did detect expression of mRNA for IL-13Ra2 in mouse
eosinophils although it was low relative to expression in the
mouse macrophage cell line, RAW 264.7. Cell surface expression
of IL-13Ra2 could not be measured due to lack of available anti-
mouse IL-13Ra2 antibodies for flow cytometry and PCR
detection is a poor predictor of receptor protein expression on
the cell surface. The other possibility is that treatment with IL-13
downregulates IL-13Ra1 on mouse eosinophils, as was observed
for human eosinophils [23].
Activation of the PI3K pathway, in particular PI3Kc, is one of
the central components of eosinophilic migration in response to
chemokines in vitro [45] and in vivo [46]. IL-4 acting through the
IRS-2 adapter protein can lead to activation of p85/p110, and
PI3K activity was observed in human eosinophils following
stimulation with IL-4 [30]. From the studies of PI3Kc-deficient
macrophages and neutrophils, it is clear that another pathway is
contributing to chemotaxis, as there is still some migration of these
cells in response to chemokine [47–50]. In addition, recent data
using siRNA knockdown of PI3Kc in human eosinophils suggested
that PI3Kc has no role in eotaxin-mediated chemotaxis but it
plays a major role in PAF-mediated chemotaxis [51]. In contrast,
chemotaxis of mouse eosinophils to eotaxin displayed almost
complete dependence upon PI3Kc [45]. Consistent with this
study, we found that wortmannin inhibited the eotaxin-1-induced
migration of mouse eosinophils almost completely (data not
shown). Thus, the contribution of the different isoforms of PI3K to
chemotaxis may depend on the particular chemokine stimulus and
appears to differ between human and mouse eosinophils. The
activation of different PI3K isoforms might be the point at which
the IL-4 and chemokine signaling pathways converge to amplify
chemotactic responses of eosinophils in vivo during an allergic
inflammatory response and we incorporated this hypothesis and
our findings into a model (Figure 8). IL-4-induced activation of
IRS-2 leads to PI3Ka and Akt activation in FDCP cells, a mouse
myeloid progenitor cell line [52]. In this regard, we noted slight
induction of serine phosphorylated AKT, a downstream target of
Figure 8. Proposed mechanism of IL-4 enhancement of mouse eosinophil chemotaxis to eotaxin. Our data showed that the STAT6 and
IRS-2 pathways are activated in mouse eosinophils in response to IL-4 (black oval) but to a lesser degree by IL-13. Engagement of CCR3 by eotaxin-1
(white oval) activates G-proteins leading to activation of PI3K isoforms and other signaling pathways. The two pathways may intersect to enhance
migration in the activation of Rho guanine nucleotide exchange factors (GEFs), which leads to cytoskeletal rearrangement and enhanced chemotaxis.
IL-4/STAT6 has been implicated in spreading/movement of B-cells via Rho GEFs [63]. IL-4 is also known to upregulate adhesion molecules involved in
extravasation/chemotaxis – this may be due to activation of STAT6-mediated transcription or activation of the AKT pathway downstream of IRS-2.
doi:10.1371/journal.pone.0039673.g008
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serine phosphorylation was observed with IL-13 stimulation.
Chemokines such as RANTES, SDF-1 and IL-8 can also activate
Akt in a PI3K-dependent manner [53–55]. Akt can phosphorylate
transcription factors such as NF-kB and can also translocate to the
nucleus itself to alter transcription, two mechanisms by which the
expression of adhesion molecules may be regulated. IL-4-induced
enhancement of eosinophil adherence to endothelial cells and
extravasation are well-documented, mainly due to upregulation of
endothelial VCAM-1, ICAM-1 and the selectins [56–58]. Another
point at which the two pathways may converge is at the level of
cytoskeletal rearrangement. There is a large literature describing
regulation of the Rho GTPase family by PI3K and leucocyte
mutants of these family members display deficient migration or
alterations in cytoskeletal rearrangement. IL-4 also induces
rearrangement of the cytoskeleton in B-cells [59], macrophages
[60] and neutrophils [61]. In B-cells, these changes are STAT6-
dependent and involve Rac1 and Cdc42 [62,63]. Another point of
convergence of IL-4- and chemokine-activated signaling could be
activation of Grb2/Sos/Ras/ERK pathway. IL-4-activated IRS-2
associates with Grb2 [64,65] and Gia-activated Src tyrosine
kinases can potentially phosphorylate adaptor proteins such as Shc
and Grb2. We however did not observe enhancement of ERK
signaling following co-stimulation with IL-4 and eotaxin-1.
In conclusion, we have shown that mouse eosinophils express all
components of the IL-4/213 receptor complexes on their surface,
they respond to IL-4 by phosphorylating IRS-2 and STAT6, and
their chemotactic responses to eotaxin-1 are enhanced by pre-
treatment with IL-4 but not with IL-13. This enhancement of
chemotaxis is dependent upon the activation of type I IL-4
receptor complexes. These data suggest that IL-4 in the
inflammatory milieu would promote increased eosinophilic re-
cruitment into the airways during an allergic immune response.
Understanding how cytokine signaling influences chemotactic
responses of these cells is important as it might provide a starting
point for rational drug design to inhibit inflammatory cell
infiltration of the airways in asthma.
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